2133364-01-7
|
|
|
- CAS号:
- 2133364-01-7
- 英文名:
- Vildagliptin dihydrate
- 英文别名:
- Vildagliptin dihydrate
- 中文名:
- 2133364-01-7
- 中文别名:
- 维达列汀二水合物;维格列汀二水合物;化合物 VILDAGLIPTIN DIHYDRATE
- CBNumber:
- CB54797105
- 分子式:
- C17H27N3O3
- 分子量:
- 321.42
- MOL File:
- 2133364-01-7.mol
|
|
|
2133364-01-7化学性质
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
Soluble in DMSO
-
|
2133364-01-7性质、用途与生产工艺
Vildagliptin dihydrate (LAF237 dihydrate) 是一种有效且稳定的选择性二肽基肽酶IV (DPP-IV) 抑制剂，在人 Caco-2 细胞中抑制 DPP-IV 的 IC50 为 3.5 nM。Vildagliptin dihydrate 具有出色的口服生物利用度和有效的降血糖活性。
IC50: 3.5 nM (DPP-IV, in human Caco-2 cells)
Vildagliptin promotes beta cell survival by inhibiting cell apoptosis. Vildagliptin also promotes cell proliferation.
Vildagliptin (35 mg/kg; once daily by oral gavage) increases plasma active GLP-1 levels in islets of db/db mice.
Vildagliptin (10 µmol/kg; orally) significantly decreases glucose excursions and stimulate insulin secretion in obese male Zucker rats.
|
Animal Model:
|
Male db/db mice (BKS) and wildtype mice
|
|
Dosage:
|
35 mg/kg
|
|
Administration:
|
Oral gavage; once daily; for 6 weeks
|
|
Result:
|
Increased plasma active GLP-1 levels (22.63±1.19 vs. 11.69±0.44).
|
|
Animal Model:
|
Obese male Zucker rats
|
|
Dosage:
|
10 µmol/kg (Pharmacokinetic Analysis)
|
|
Administration:
|
Orally
|
|
Result:
|
Significantly decreased glucose excursions and stimulate insulin secretion.
|
2133364-01-7
上下游产品信息
上游原料
下游产品
2133364-01-7, 2133364-01-7 相关搜索:
- 化合物 VILDAGLIPTIN DIHYDRATE
- 维达列汀二水合物
- 维格列汀二水合物
- 2133364-01-7
- Vildagliptin dihydrate